REG - PureTech Health PLC - Transaction in Own Shares
21/07/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220721:nRSU2094Ta&default-theme=true
RNS Number : 2094T PureTech Health PLC 21 July 2022
21 July 2022
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.
Date of purchase: 20 July 2022
Number of ordinary shares purchased: 60,212
Highest price paid per share: 194.00p
Lowest price paid per share: 193.00p
Volume weighted average price paid per share: 193.94p
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have 3,538,835 ordinary
shares in treasury and has 285,072,285 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 285,072,285, which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering,
developing and commercializing highly differentiated medicines for devastating
diseases, including inflammatory, fibrotic and immunological conditions,
intractable cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has created a
broad and deep pipeline through the expertise of its experienced research and
development team and its extensive network of scientists, clinicians and
industry leaders.
This pipeline, which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 27 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization, as of the date of PureTech's most recently filed
Annual Report and corresponding Form 6-K. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points based on unique insights in immunology and drug
development.
For more information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number
20/07/2022 15:07:10 357 194 XLON 00310152003TRLO1.1.1
20/07/2022 15:07:05 41 194 AQXE 00310151987TRLO1.1.1
20/07/2022 15:07:02 115 193.8 XLON 00310151977TRLO1.1.1
20/07/2022 15:07:02 302 193.8 XLON 00310151976TRLO1.1.1
20/07/2022 15:06:09 37 194 AQXE 00310151629TRLO1.1.1
20/07/2022 15:06:09 37 194 AQXE 00310151628TRLO1.1.1
20/07/2022 15:06:08 413 194 CHIX 00310151625TRLO1.1.1
20/07/2022 15:06:08 445 194 CHIX 00310151623TRLO1.1.1
20/07/2022 15:06:06 357 194 XLON 00310151614TRLO1.1.1
20/07/2022 15:06:06 394 194 XLON 00310151612TRLO1.1.1
20/07/2022 15:06:06 357 194 XLON 00310151613TRLO1.1.1
20/07/2022 15:06:06 294 194 XLON 00310151611TRLO1.1.1
20/07/2022 15:06:06 394 194 XLON 00310151610TRLO1.1.1
20/07/2022 15:06:06 14 194 XLON 00310151608TRLO1.1.1
20/07/2022 15:06:06 49 194 XLON 00310151609TRLO1.1.1
20/07/2022 15:06:06 3416 194 XLON 00310151607TRLO1.1.1
20/07/2022 15:06:06 343 194 XLON 00310151606TRLO1.1.1
20/07/2022 15:06:06 8 194 XLON 00310151605TRLO1.1.1
20/07/2022 15:06:04 319 194 XLON 00310151539TRLO1.1.1
20/07/2022 15:06:04 16 194 XLON 00310151538TRLO1.1.1
20/07/2022 15:06:04 353 194 XLON 00310151537TRLO1.1.1
20/07/2022 15:06:04 114 194 XLON 00310151536TRLO1.1.1
20/07/2022 15:06:04 17 194 CHIX 00310151535TRLO1.1.1
20/07/2022 15:06:04 74 194 BATE 00310151527TRLO1.1.1
20/07/2022 15:06:04 60 194 CHIX 00310151524TRLO1.1.1
20/07/2022 15:06:04 46 194 CHIX 00310151526TRLO1.1.1
20/07/2022 15:06:04 60 194 CHIX 00310151525TRLO1.1.1
20/07/2022 15:06:04 12 194 CHIX 00310151522TRLO1.1.1
20/07/2022 15:06:04 57 194 CHIX 00310151523TRLO1.1.1
20/07/2022 15:06:04 71 194 CHIX 00310151520TRLO1.1.1
20/07/2022 15:06:04 60 194 CHIX 00310151521TRLO1.1.1
20/07/2022 15:06:04 71 194 CHIX 00310151517TRLO1.1.1
20/07/2022 15:06:04 71 194 CHIX 00310151518TRLO1.1.1
20/07/2022 15:06:04 67 194 BATE 00310151515TRLO1.1.1
20/07/2022 15:06:04 71 194 CHIX 00310151516TRLO1.1.1
20/07/2022 15:06:04 71 194 BATE 00310151513TRLO1.1.1
20/07/2022 15:06:04 82 194 BATE 00310151514TRLO1.1.1
20/07/2022 15:06:04 280 194 BATE 00310151511TRLO1.1.1
20/07/2022 15:06:04 142 194 BATE 00310151512TRLO1.1.1
20/07/2022 15:06:04 82 194 BATE 00310151510TRLO1.1.1
20/07/2022 15:06:04 71 194 BATE 00310151509TRLO1.1.1
20/07/2022 15:06:03 57 194 CHIX 00310151508TRLO1.1.1
20/07/2022 15:06:03 1299 194 BATE 00310151473TRLO1.1.1
20/07/2022 15:06:02 518 194 BATE 00310151468TRLO1.1.1
20/07/2022 15:06:02 227 194 XLON 00310151460TRLO1.1.1
20/07/2022 15:06:02 12 194 XLON 00310151459TRLO1.1.1
20/07/2022 15:06:02 335 194 XLON 00310151458TRLO1.1.1
20/07/2022 15:06:02 375 194 XLON 00310151457TRLO1.1.1
20/07/2022 15:06:02 131 194 XLON 00310151456TRLO1.1.1
20/07/2022 15:06:02 269 194 XLON 00310151455TRLO1.1.1
20/07/2022 15:06:02 204 194 XLON 00310151453TRLO1.1.1
20/07/2022 15:06:02 66 194 XLON 00310151454TRLO1.1.1
20/07/2022 15:06:02 407 194 XLON 00310151452TRLO1.1.1
20/07/2022 15:06:02 388 194 XLON 00310151451TRLO1.1.1
20/07/2022 15:06:02 388 194 XLON 00310151450TRLO1.1.1
20/07/2022 15:06:02 393 194 XLON 00310151449TRLO1.1.1
20/07/2022 15:06:02 301 194 XLON 00310151448TRLO1.1.1
20/07/2022 15:06:02 48 194 CHIX 00310151447TRLO1.1.1
20/07/2022 15:06:02 106 194 XLON 00310151446TRLO1.1.1
20/07/2022 15:06:02 336 194 XLON 00310151445TRLO1.1.1
20/07/2022 15:06:02 68 194 BATE 00310151444TRLO1.1.1
20/07/2022 15:06:02 17 194 CHIX 00310151443TRLO1.1.1
20/07/2022 15:06:02 354 194 XLON 00310151442TRLO1.1.1
20/07/2022 15:06:02 336 194 XLON 00310151441TRLO1.1.1
20/07/2022 15:05:39 344 194 BATE 00310151305TRLO1.1.1
20/07/2022 15:05:38 37 194 AQXE 00310151302TRLO1.1.1
20/07/2022 15:05:38 384 194 BATE 00310151303TRLO1.1.1
20/07/2022 15:05:38 37 194 AQXE 00310151301TRLO1.1.1
20/07/2022 15:05:13 44 194 AQXE 00310151213TRLO1.1.1
20/07/2022 15:05:13 44 194 AQXE 00310151212TRLO1.1.1
20/07/2022 15:05:13 314 194 BATE 00310151211TRLO1.1.1
20/07/2022 15:01:19 6 194 BATE 00310150067TRLO1.1.1
20/07/2022 15:01:19 23 194 BATE 00310150068TRLO1.1.1
20/07/2022 15:01:19 43 194 CHIX 00310150066TRLO1.1.1
20/07/2022 15:01:19 45 194 AQXE 00310150064TRLO1.1.1
20/07/2022 15:01:19 40 194 AQXE 00310150065TRLO1.1.1
20/07/2022 15:01:19 44 194 AQXE 00310150063TRLO1.1.1
20/07/2022 15:01:19 37 194 AQXE 00310150062TRLO1.1.1
20/07/2022 15:01:18 136 194 BATE 00310150061TRLO1.1.1
20/07/2022 15:01:18 40 194 AQXE 00310150060TRLO1.1.1
20/07/2022 15:00:04 67 194 BATE 00310149724TRLO1.1.1
20/07/2022 15:00:04 380 194 BATE 00310149725TRLO1.1.1
20/07/2022 14:33:20 246 193 CHIX 00310142892TRLO1.1.1
20/07/2022 14:33:20 66 193 CHIX 00310142890TRLO1.1.1
20/07/2022 14:33:20 94 193 AQXE 00310142891TRLO1.1.1
20/07/2022 14:33:19 47 193 AQXE 00310142888TRLO1.1.1
20/07/2022 14:33:19 68 193 CHIX 00310142889TRLO1.1.1
20/07/2022 14:33:19 47 193 AQXE 00310142887TRLO1.1.1
20/07/2022 14:32:59 379 193 CHIX 00310142704TRLO1.1.1
20/07/2022 14:31:40 549 193 CHIX 00310142166TRLO1.1.1
20/07/2022 14:31:40 736 193 CHIX 00310142165TRLO1.1.1
20/07/2022 14:31:40 68 193 CHIX 00310142164TRLO1.1.1
20/07/2022 14:31:39 40 193.4 AQXE 00310142162TRLO1.1.1
20/07/2022 14:31:39 37 193.4 AQXE 00310142163TRLO1.1.1
20/07/2022 14:31:39 45 193.4 AQXE 00310142161TRLO1.1.1
20/07/2022 14:31:39 45 193.4 AQXE 00310142160TRLO1.1.1
20/07/2022 14:31:39 45 193.4 AQXE 00310142159TRLO1.1.1
20/07/2022 14:31:39 621 193.4 AQXE 00310142158TRLO1.1.1
20/07/2022 14:31:38 6867 194 XLON 00310142155TRLO1.1.1
20/07/2022 14:31:38 5462 194 XLON 00310142156TRLO1.1.1
20/07/2022 14:31:38 336 194 XLON 00310142154TRLO1.1.1
20/07/2022 14:31:37 1552 194 XLON 00310142110TRLO1.1.1
20/07/2022 14:31:37 979 194 XLON 00310142109TRLO1.1.1
20/07/2022 14:31:37 832 194 XLON 00310142108TRLO1.1.1
20/07/2022 14:31:37 6288 194 XLON 00310142107TRLO1.1.1
20/07/2022 14:31:37 13955 194 XLON 00310142106TRLO1.1.1
20/07/2022 14:31:37 347 194 XLON 00310142105TRLO1.1.1
20/07/2022 14:31:35 26 194 XLON 00310142097TRLO1.1.1
20/07/2022 14:31:35 47 194 XLON 00310142096TRLO1.1.1
20/07/2022 14:31:35 796 194 XLON 00310142095TRLO1.1.1
20/07/2022 14:31:35 343 194 XLON 00310142094TRLO1.1.1
20/07/2022 14:31:24 439 193.4 AQXE 00310142024TRLO1.1.1
20/07/2022 14:06:23 470 193.4 AQXE 00310137432TRLO1.1.1
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSFLFLDDDIIFIFRecent news on Puretech Health
See all newsREG - PureTech Health PLC - Notice of Results
AnnouncementRCS - PureTech Health PLC - PRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024
AnnouncementRCS - PureTech Health PLC - FDA Grants PRTC's LYT-200 Fast Track Designation
AnnouncementREG - PureTech Health PLC - PRTC Launches Seaport w/ $100M; Leadership Changes
AnnouncementREG - PureTech Health PLC - $100M Tender Offer
Announcement